Device Trial Radar · NCT07939061
Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
47
Planned (sponsor's estimate)
Start
Sep 3, 2026
Primary completion
Jun 1, 2028
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- General University Hospital, PragueAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 7 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.
Conditions
- Overactive Bladder
- Daytime Urinary Incontinence
Interventions
Active peroneal transcutaneous neuromodulation (URIS I, Stimvia)Device
Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal.
Sham peroneal transcutaneous neuromodulation (URIS I, Stimvia)Device
Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of clinical responders at the end of treatmentTime frame: Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
General University Hospital
Prague, Czechia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.